和铂医药(2142.HK)专利有效性获国家知识产权局确认 侵权诉讼持续推进

格隆汇
Yesterday
和铂医药(2142.HK)今日公布其核心专利维权行动的最新进展。针对百奥赛图(北京)医药科技股份有限公司就和铂医药 “结合分子”专利权(专利号:CN201210057668.0)提出的无效宣告请求,国家知识产权局依据相关规定于2025年6月5日作出审查决定:维持该专利权有效。该专利涉及一种利用转基因动物制备全人源仅重链抗体(HCAb)的方法。
和铂医药创始人、董事长兼首席执行官王劲松博士表示:“此次国家知识产权局的审查决定是对和铂医药核心知识产权源头创新价值的正当保护。目前,和铂医药已构建起覆盖全球核心市场的专利壁垒,切实保护Harbour Mice®及其他技术平台的研发投入与创新成果。未来,我们期待携手更多合作伙伴,以HCAb专利技术为引擎,加速创新疗法突破,惠及全球患者。”

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10